

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

Antibacterial Resistance Leadership Group (ARLG) Publication Policy

I. Introduction:

The ARLG Publication Policy directs the review and approval of all publications, presentations, meeting abstracts, media interviews or requests for quotes, press releases, or social media or other web site posts intended to report ARLG supported research or to represent ARLG.

Unless stated more specifically below, the terms ‘publications’ and ‘presentations’ are inclusive of all the activities listed above.

II. Purpose:

This Policy documents the role and membership of the ARLG Publications Committee, the process of review, and the requirements for approval pertaining to publications and presentations intended to represent ARLG or to report research supported by ARLG.

III. Scope:

This Policy applies to all individuals involved in developing publications or presentations derived from work supported in total or in part by ARLG funds, using ARLG Laboratory Center (LC) biospecimens or data provisioned by ARLG Statistical and Data Management Center (SDMC), or intended to represent the ARLG.

IV. Definitions:

Affiliated Studies	Studies that utilize some assay results or data generated as part of an ARLG study, or require analysis time from an ARLG statistician or scientific input from an ARLG-funded individual or transient/limited funding (but the majority of the effort and data were funded using alternate sources). Examples include ESI Seed Grants, transient studies (studies whereby support may supplement funding until closure), and diagnostics or industry studies that utilize intellectual property or resources from ARLG
ARLG	Antibacterial Resistance Leadership Group
ARLG LC Biospecimens	Bacterial strains or other biospecimens provided to investigators through the ARLG Laboratory Center or generated from ARLG-funded studies
ARLG Studies	Studies that are approved by the ARLG Executive Committee, and which receive significant contributions or support in design and/or execution and analysis (either monetarily or with resources from the Laboratory Center, Statistics and Data Management Center, Clinical Operations Center, or by ARLG faculty consultation)
COC	Clinical Operations Center
CPM	Clinical Project Manager
DMID	Division of Microbiology and Infectious Diseases, NIAID, NIH
ESI	Early Stage Investigator
ICMJE	International Committee of Medical Journal Editors

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

ID	Identification
LC	Laboratory Center
NIAID	The National Institute of Allergy and Infectious Diseases
NIH	The National Institutes of Health
PI	Principal Investigator
PL	Project Leader
Primary Manuscripts/ Abstracts	Manuscripts or abstracts that report data and results of the primary objectives of an ARLG study
SC	Steering Committee
SDMC	Statistical and Data Management Center
Secondary Manuscripts/ Abstracts	Manuscripts or abstracts that report secondary analysis results or objectives of an ARLG study, or scientific questions outside of the primary objectives (e.g., baseline data reports, secondary objectives specified in the protocol, cross-protocol data, or analysis of data or specimens collected as part of a study, but used for analyses not previously specified in the primary protocol)

V. Policy:

All manuscripts, abstracts, presentations at scientific meetings (in format of slides or posters), and any other publications including web-only articles, and electronic transmissions to any public domain, derived from work supported in total or in part by ARLG funds, using ARLG biospecimens or datasets, or intended to represent the ARLG (i.e., “publications” or “presentations”) must, before submission to a scientific journal, conference, organization, or other publishing body, or before being posted in a public domain, be submitted to the ARLG Publications Committee and routed for ARLG review as detailed below.

A. Role and Membership of the ARLG Publications Committee

It is the policy of the Publications Committee that appropriate acknowledgement of ARLG contributions is cited and, in certain circumstances, that the study results are presented by individuals who have working knowledge of the study design, implementation, data synthesis/analysis, and interpretation as intended. The goals of the Publications Committee are to ensure that any confidential or proprietary information is protected, and that appropriate statistical analyses are executed.

The Publications Committee serves to approve the Publication Policy (subject to ARLG Executive Committee final approval); define the purpose of ARLG review, what has to be reviewed, and the review process; resolve conflict if it occurs among the authors (see Section B.2.1); and decide on the final disposition for publications not meeting acceptable review criteria [as determined by the reviewer(s)]. In addition, the Publications Committee can develop strategies for additional studies and ongoing research, and review proposed topics for methods papers, review papers, and opinion articles from ARLG members. Publications Committee members may serve as reviewers for data sharing requests as deemed necessary by the Publications Committee Chair.

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

The Publications Committee Chair appoints the reviewers and brings issues or policy concerns to the Committee as needed.

The Publications Committee consists of all the members of the ARLG Steering Committee (SC). The Chair and Vice-Chair of the ARLG SC serve as the Chair and Vice-Chair of the ARLG Publications Committee. The Publications Committee consists of:

- ARLG Co-Principal Investigators
- ARLG SDMC Director and Associate Director
- ARLG Clinical Operations Center (COC) Director and Associate Directors
- ARLG Mentoring Committee Chair
- ARLG Laboratory Center Director and Associate Director
- ARLG Scientific Leadership Center Directors and Associate Directors
- Chairs of the ARLG Scientific Subcommittees:
 - Gram Positive
 - Gram Negative
 - Diagnostics
- Chairs of ARLG Working Groups for:
 - Pediatrics
 - Pharmacokinetics
 - Immunocompromised Host
 - Innovations
- Innovations Working Group Experts on:
 - Gram Positive Strategy Trials
 - Gram Negative Strategy Trials
 - Diagnostics Strategy Trials
- ARLG Fellow
- NIAID/DMID members:
 - Bacteriology and Mycology Branch Chief
 - ARLG Program Officer
 - Clinical Project Managers
 - Medical Officers
 - Translational Sciences Chief

Lauren Komarow, member of the ARLG SDMC and Data Sharing Committee Chair, will attend the Publications Committee meetings when data sharing requests are discussed.

The Publications Committee Manager is Brooke Walker (919-660-8477; brooke.walker@duke.edu).

The Publications Committee will meet face-to-face annually, and ad hoc as needed. During these meetings, the committee will review and revise the Policy as needed, review the ARLG publications reports, and develop strategies for additional studies and publications from ARLG members.

The Publications Committee shall continue until the end of the grant. Should the Publications Committee disband, all publications thereafter shall be submitted to the ARLG Co-Principal Investigators for review and comment.

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

B. Publications

1. Requirements

All publications must conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (International Committee of Medical Journal Editors [ICMJE]) with regard to authorship, disclosure, scientific integrity, and other requirements. All public presentations shall be consistent with usual academic standards. As a reminder, all applicable clinical trials must be registered in [ClinicalTrials.gov](https://clinicaltrials.gov) at or before enrollment of the first subject.

2. Authorship

All authors listed should have contributed significantly to the design and development, statistical design or analysis, laboratory methodology, or any other significant operational or scientific aspect of the study per [ICMJE guidelines](#).

These may include the following:

- Protocol Principal Investigator
- Lead statistician performing the analysis
- Clinical site investigators with significant contributions of samples, data, or enrolled patients
- Other authors who meet the authorship criteria of peer-reviewed scientific journals

For primary and secondary manuscripts from ARLG studies (see Section IV Definitions), “*on behalf of The Antibacterial Resistance Leadership Group*” must be listed after the last author.

If required by the journal publisher, the authors may provide a list of ARLG members by name for the Acknowledgment section. This list, which is not exhaustive, may include, for ex. the ARLG SC members, or members of the operations team and other significant contributors, if they are not co-authors. The authors must request the current list of ARLG SC by name from the Publications Committee Manager.

2.1. Conflict Resolution

Disagreements or other conflicts about first, second, senior, or other authorship of the publication or presentation of results derived from work supported in total or in part by ARLG funds, or intended to represent the ARLG, will be resolved by the ARLG Publications Committee, whose decision will be final. Members in conflict with study authors will recuse themselves from the committee review process. In case of a tie, the Publications Committee Chair will hold the tie-breaking vote.

3. Acknowledgements

3.1 Publications from ARLG Studies and Affiliated Studies

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

The following must be stated to acknowledge funding for ARLG studies (see Section IV Definitions):

“Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

For publications arising from affiliated studies (see Section IV Definitions), the acknowledgement should be modified to state the following:

“Research reported in this publication was supported in part by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

3.2 Publications Authored by ARLG Fellows

ARLG Fellows should acknowledge financial support from ARLG in all publications during their fellowship and not only in those directly related to ARLG or affiliated studies, and they should submit these publications to the ARLG Publications Committee (see Table 1 for details). Manuscripts reporting results of studies or work not supported by ARLG for which the Fellow is an author or co-author will be evaluated by the Publications Committee Manager for compliance with the statement of acknowledgement, but will not be reviewed.

The following statement of acknowledgment must be included in all publications by ARLG Fellows:

“[Fellow’s name/initials] was supported by an Antibacterial Resistance Leadership Group fellowship [National Institute of Allergy and Infectious Diseases UM1AI104681]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

If the ARLG Fellowship provides only partial support, the following must be stated:

“[Fellow’s name/initials] was supported in part by an Antibacterial Resistance Leadership Group fellowship [National Institute of Allergy and Infectious Diseases UM1AI104681].

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

3.3 Publications Authored by Early Stage Investigator (ESI) Seed Grant Recipients, Early Faculty Seedling Award Recipients, and Trialists-in-Training

ESI Seed Grant recipients, Early Faculty Seedling award recipients, and Trialists-in-Training should acknowledge financial support from the ARLG only in publications derived from ARLG-funded studies, and they should submit these publications to the ARLG Publications Committee for review (see Table 1 for details).

The following statement of acknowledgment must be included in these publications:

“Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

Grantees (other than ARLG Fellows) who would like to acknowledge their source of effort when they present on non-ARLG funded studies, may use the following statement of acknowledgement (optional):

“[Grantee’s name/initials] was supported in part by an Antibacterial Resistance Leadership Group award [National Institute of Allergy and Infectious Diseases UM1AI104681]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

3.4 Reference of ARLG Laboratory Center Biospecimens

ARLG bacterial strains (or other ARLG LC biospecimens) (see Section IV Definitions) must be referenced by their ARLG-assigned ID number in all publications.

The recipient scientist should provide appropriate acknowledgment in all publications and presentations by use of the following language:

“Bacterial isolates [or specify other specimens] identified as “ARLG” were provided by the [Antibacterial Resistance Leadership Group Laboratory Center](#), which is supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

For ARLG studies that report results on bacterial isolates that will be deposited to the ARLG Biorepository, after the appropriate funding acknowledgment (see Sections B.3.1-B.3.3), the following statement should be included:

“Bacterial isolates reported in this study may be available, subject to approval, through a request to the [Antibacterial Resistance Leadership Group Laboratory Center](#), which is supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681.”

3.5 Data Provision

For publications arising from affiliated studies that used data provisioned by the ARLG SDMC (no funding) for secondary analysis, the following acknowledgement should be used:

“Data from the [Study Acronym] study was provided by the Antibacterial Resistance Leadership Group (ARLG). The ARLG is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

3.6 Data Availability Statement

For all primary and applicable secondary manuscripts (i.e., those that the ARLG holds the primary and analysis datasets in the data repository), a data availability statement should be added in the Acknowledgment Section. For example:

“Individual deidentified participant data (and supporting documentation, data dictionaries, and protocol) that underlie the results in this article can be made available to investigators following submission of a plan for data use, approval by the ARLG or designated entity, and execution of required institutional agreements. Provision might be contingent upon the availability of funding for data preparation and deidentification. More information can be found at: <https://arlg.org/request-data/>. Sequences will be publicly available through the National Center for Biotechnology Information (accession number [Accession Number];[URL]).”

For additional guidance, please contact the Publications Committee Manager.

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

C. Presentations

The study principal investigator or other team member presenting data from ARLG studies or other ARLG research work as an oral or poster presentation at scientific meetings must use the ARLG logo and acknowledge the grant using the appropriate acknowledgement statement (see Section B.3 Acknowledgments).

The ARLG logo, template slides, and template poster are available upon request to the Publications Committee Manager.

D. Submissions

All submissions to the ARLG Publications Committee, at any stage of review, are to be made through the ARLG Publications Committee Manager. Manuscripts and abstracts should be submitted via email in an editable electronic format, such as Microsoft Word. The author is notified of receipt by e-mail.

The Publications Committee Manager will review all submissions for proper citation of ARLG contributions. For submissions involving ARLG studies, affiliated studies, studies funded through an ARLG Fellowship, ESI Seed Grant, Early Faculty Seedling award, or ARLG-funded studies authored by Trialists-in-Training, the publication will be further routed to the ARLG Publications Committee Chair for review assignment. All submitted publications will be tracked.

When the reviewers have been selected, the Publications Committee Manager will confirm with the submitter whether a conflict of interest exists with the reviewers. The Publications Committee Manager will ensure that the publication is not circulated to the conflicted member.

Authors must report the final disposition (e.g., acceptance, rejection, resubmission to an alternate journal, etc.) of publications to the Publications Committee Manager.

Publications for studies only using ARLG LC biospecimens should be routed to the ARLG LC (ARLG-Lab-Center-Operations@dm.duke.edu) for review to ensure compliance with the acknowledgment and Material Transfer Agreement requirements.

Publications for studies using data provisioned by the ARLG SDMC should be routed to Lauren Komarow (lkomarow@bsc.gwu.edu) for review to ensure compliance with the acknowledgement and Data Transfer Agreement requirements.

All questions regarding the need for review by the Publications Committee, the timelines, and the status of a review should be addressed to the Publications Committee Manager.

E. Review Process

Upon receipt of a submission, the Publications Committee Chair shall assign at least two reviewers for each manuscript and at least one reviewer for each abstract, poster or slide presentation, or other publication that qualifies for ARLG review. Reviewers will be selected from among ARLG committee members according to their expertise. Each

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

assigned reviewer has the right to delegate review to a designee with an appropriate level of expertise.

The purpose of the ARLG review is to assure that the manuscript is accurate and appropriate in its methods and reporting, interpretation of results, and that the appropriate acknowledgment has been cited. Reviewer(s) will review the author line with the standard criteria for scientific authorship in mind, determine whether conflicts of interest exist, and assess the balance and accuracy of data presentation and results. The reviewer(s) shall consider each publication with due regard for the scientific merit of the proposed publication with the aim of promoting the timely dissemination of scientific and medical knowledge. Reviewers may, but are not required to, function as though they were a peer reviewer for a journal and provide additional comments, wordsmithing, etc., to aid the authors, but this is not the main responsibility (see Appendix).

The Publications Committee Manager will facilitate correspondence between reviewers and the primary author(s) of each publication. Otherwise, the Publications Committee Manager should be copied on all correspondence between the reviewers and the primary author(s).

Publications not meeting acceptable review criteria will be referred to the Publications Committee for final determination of suitability for publication. In the situation that the Publications Committee does not endorse a proposed manuscript or presentation, the author still maintains the right to present locally collected, generated, or analyzed data. However, the author may not include aggregate ARLG study results without Publications Committee approval and must include the following disclaimer:

“This [publication type] is not endorsed by the ARLG Publications Committee.”

Time allowed for review is 10 working days for manuscripts and presentations from ARLG or affiliated studies. In the event that the Publications Committee does not respond within 30 calendar days, the authors are free to proceed with the publication or the presentation. Abstracts must be submitted at least 5 working days prior to the abstract submission deadline (see Table 1 for details). In the event that the Publications Committee does not respond within 5 working days, the authors are free to proceed with the submission of the abstract to a scientific meeting or conference.

Only those review comments received on time will be considered. The review time begins when the draft publication is sent to reviewer(s) by the ARLG Publications Committee Manager.

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

Table 1. Timelines for ARLG Publications Review

Publication Type	Submission to ARLG	ARLG to NIAID/DMID
Manuscripts and presentations (slides and posters) from ARLG or affiliated studies	10 working days prior to submission or presentation	<i>N/A (NIAID/DMID included in Publications Committee)</i>
Abstracts from ARLG or affiliated studies	At least 5 working days prior to submission	<i>N/A (NIAID/DMID included in Publications Committee)</i>
Manuscripts from ARLG Fellows as author or co-author not involving ARLG or affiliated studies	5 working days prior to submission Publications Committee Manager will review for compliance with the acknowledgment statement. These will be not be reviewed by the Publications Committee.	<i>N/A</i>
Publications (manuscripts and abstracts) from studies using ARLG LC biospecimens	As detailed in the Material Transfer Agreement. These publications will be routed to ARLG LC for review (see Section D).	<i>N/A</i>
Publications (manuscripts and abstracts) from studies using data provisioned by ARLG SDMC	As detailed in the Material Transfer Agreement. These publications will be routed to Lauren Komarow for review (see Section D).	<i>N/A</i>
Press releases/social media publicity	5 working days, or per contractual agreement (as applicable).	<i>NIAID/DMID Program Officer, CPM to review</i>

F. Publicity and Media

Media inquiries and press releases must be first reviewed by the Protocol PI involved (as applicable), or other ARLG representative, the Protocol PL (if applicable), anyone quoted in the release, and then referred to the NIAID/DMID Program Officer and the NIAID/DMID CPM (if applicable). The NIAID/DMID Program Officer or CPM will ensure NIAID/DMID review (see Table 1 for details). Protocol PLs will consult relevant contractual agreements and follow additional applicable requirements. The Protocol PL will ensure Duke University review by the Director, Marketing Communications, Sarah Avery (sarah.avery@duke.edu), or designees. If these contacts are no longer available, the Protocol PL should consult with DCRI communications.

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

For social media publicity, ARLG Publications Committee review is required only for those announcements that report a research finding **without** the vetted poster/abstract/presentation/publication/press release, etc. attached.

G. Review by Industry Partners Prior to Publication

It is the responsibility of the Protocol PI or the Lead Author to ensure, in consultation with the Protocol PL or DMID CPM (as applicable), that a) contractual terms on the review of publications (manuscript, abstract, poster, presentation, press release, or other media requests) by industry partner(s) involved in the research project are followed, and b) the industry partner(s) have had the opportunity to review before publication.

H. Fundamental Errors in Published Works

Should an author discover a significant error or inaccuracy in a published work from an ARLG or affiliated study, the author should promptly notify the ARLG Publications Committee Manager.

I. NIH Public Access Policy Compliance

All authors must follow the National Institutes of Health (NIH) [Public Access Policy](#). For questions regarding the policy, please see the NIH Public Access Policy [Frequently Asked Questions](#).

The Publications Committee Manager will ensure that all published manuscripts are submitted to PubMed Central, as required. (For a list of journals that automatically submit articles to PubMed Central, please visit https://publicaccess.nih.gov/submit_process_journals.htm.)

Since all ARLG publications will be deposited in PubMed Central, it is not necessary to select Open Access, and in doing so additional unnecessary fees may be incurred. Authors should not select Open Access without a specific reason. Any rationale for requesting Open Access should be submitted to the Publications Committee Manager for approval in advance of the submission.

As part of the NIH policy, authors are responsible for:

- a) **Copyright compliance** - Authors must ensure that agreements with publishers permit the submission of the author's manuscript to NIH. Upon submitting your manuscript to the journal, please alert the publisher to the fact that the manuscript is subject to NIH policy.
- b) **Citing PubMed Central ID numbers** - When a manuscript is submitted to the NIH, the publication will receive an NIH Manuscript Submission (NIHMS) ID number. Once a manuscript is available in PubMed Central, it will be assigned a PubMed Central ID number. Effective May 25, 2008, authors must cite PubMed Central ID or (NIHMS ID) numbers for any articles cited in progress reports, new applications, and renewals.

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

VI. References:

1. Submit Studies to ClinicalTrials.gov at:
<https://www.clinicaltrials.gov/>
2. International Committee of Medical Journal Editors, Clinical Trials Registration at:
<https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html>
3. International Committee of Medical Journal Editors, Recommendations for authors at:
<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>
4. NIH Public Access Policy at: <https://publicaccess.nih.gov/policy.htm>
5. Frequently Asked Questions about the NIH Public Access Policy at:
<https://publicaccess.nih.gov/FAQ.htm>
6. List of journals that automatically submit articles to PubMed Central at:
https://publicaccess.nih.gov/submit_process_journals.htm

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

VII. History of Change:

Section Affected	Changes Made v4.0 to v5.0
V.A. Role and Membership of the ARLG Publications Committee	Removed <i>Diversity Working Group</i>
V.B.3 Acknowledgements	Removed reference to <i>EVERYONE award</i>
V.D. Submissions	Removed reference to <i>EVERYONE award</i>
V.E. Review Process	Added statement: In the event that the Publications Committee does not respond within 30 calendar days, the authors are free to proceed with the publication or the presentation. In the event that the Publications Committee does not respond within 5 working days, the authors are free to proceed with the submission of the abstract to a scientific meeting or conference.

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

Signatories

Lead Author (Name, Role)	Signature and Date
Maria Souli, M.D., PhD, PMP Project Leader	<i>Maria Souli</i> <i>Electronically signed by: Maria Souli</i> <i>Reason: Authored this document.</i> <i>Date: Mar 24, 2025 10:23 EDT</i>
Authorizer (Name, Role)	Signature and Date
Heather Cross, DPhil ARLG COC Director	<i>Heather R Cross</i> <i>Electronically signed by: Heather R Cross</i> <i>Reason: Approved by ARLG Executive Committee 20-Mar-2025</i> <i>Date: Mar 24, 2025 10:40 EDT</i>

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

VIII. Appendix

Instructions for Reviewers of ARLG Publications, Presentations, and Meeting Abstracts Intended to Represent ARLG-Supported Studies

- Provide your review or communicate any issues or concerns to Publications Committee Manager, Brooke Walker (919-660-8477; brooke.walker@duke.edu)
- You should recuse yourself and notify the Publications Committee Manager if you identify a conflict
- Provide your review in accordance with timeline indicated below:

Type of publication	Timeline for review
Manuscript, Slide, and Poster presentations	10 working days
Abstract	5 working days

- You may delegate the review to a designee with an appropriate level of expertise
- The purpose of the ARLG review is to ensure that the manuscript is accurate and appropriate in its methods, and reporting and interpretation of results, not whether it should be accepted or rejected for publication by a journal
- It is not your main responsibility, and you are not required to do so, but you may provide additional comments, wordsmithing, etc., to aid the authors
- Checklist for your review process:

Is the appropriate statement for acknowledgment cited?

For ARLG studies:

“Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

For affiliated studies:

“Research reported in this publication was supported in part by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

For studies authored by Fellows:

Antibacterial Resistance Leadership Group	
Document No.: ARLG-P001	Version No.: 5.0
Type: Policy	Version Date: 24-Mar-2025
Title: ARLG Publication Policy	Effective Date: 24-Apr-2025

“[Fellow’s name/initials] was supported by an Antibacterial Resistance Leadership Group fellowship [National Institute of Allergy and Infectious Diseases UM1AI104681]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

For studies authored by Fellows who received only partial support by ARLG:

“[Fellow’s name/initials] was supported in part by an Antibacterial Resistance Leadership Group fellowship [National Institute of Allergy and Infectious Diseases UM1AI104681]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

- Does the author line comply with the standard criteria for scientific authorship ([ICMJE guidelines](#))?
- For a primary or secondary manuscript from an ARLG study, is “on behalf of *The Antibacterial Resistance Leadership Group*” listed after the last author?
- Is there a conflict of interest not appropriately disclosed?
- Assess the balance and accuracy of data presentation and results, and their overall scientific integrity
- Consider the scientific merit of the proposed publication with the aim of promoting the timely dissemination of scientific and medical knowledge
- If applicable, is there a data availability statement?










ARLG-P001_ Publication Policy_v5.0_24MAR2025_Final

Final Audit Report

2025-03-24

Created:	2025-03-24 (Eastern Daylight Time)
By:	Maria Souli (ms708@duke.edu)
Status:	Signed
Transaction ID:	CBJCHBCAABAAh62qO1bHawrcVL971zBs_wEUD0u_xAPm

"ARLG-P001_ Publication Policy_v5.0_24MAR2025_Final" History

-  Document created by Maria Souli (ms708@duke.edu)
2025-03-24 - 10:18:34 AM EDT- IP address: 136.226.53.25
-  Document emailed to maria.souli@duke.edu for signature
2025-03-24 - 10:19:40 AM EDT
-  Email viewed by maria.souli@duke.edu
2025-03-24 - 10:22:50 AM EDT- IP address: 104.47.56.254
-  Signer maria.souli@duke.edu entered name at signing as Maria Souli
2025-03-24 - 10:23:14 AM EDT- IP address: 136.226.53.25
-  Document e-signed by Maria Souli (maria.souli@duke.edu)
Signing reason: Authored this document.
Signature Date: 2025-03-24 - 10:23:16 AM EDT - Time Source: server- IP address: 136.226.53.25
-  Document emailed to heather.cross@duke.edu for signature
2025-03-24 - 10:23:18 AM EDT
-  Email viewed by heather.cross@duke.edu
2025-03-24 - 10:35:51 AM EDT- IP address: 104.47.57.254
-  Signer heather.cross@duke.edu entered name at signing as Heather R Cross
2025-03-24 - 10:40:53 AM EDT- IP address: 136.226.69.29
-  Document e-signed by Heather R Cross (heather.cross@duke.edu)
Signing reason: Approved by ARLG Executive Committee 20-Mar-2025
Signature Date: 2025-03-24 - 10:40:55 AM EDT - Time Source: server- IP address: 136.226.69.29

✔ Agreement completed.

2025-03-24 - 10:40:55 AM EDT